Infection with adenovirus, a common childhood virus, is the leading hypothesis for recent cases of severe hepatitis of unknown origin in children that have led to at least six deaths, U.S. health officials said on May 20.
COVID worsens asthma in children; booster after infection not as beneficial vs OmicronAsthma, BNT162b2 (Pfizer and BioNTech), Children, COVID-19 booster shots, COVID-19 Studies, COVID-19 Vaccines, Doctors, Journal of Allergy and Clinical Immunology: In Practice, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), Polymerase Chain Reaction (PCR), R&D
Asthma in children may worsen after an infection with the coronavirus, doctors warn. Additionally, among people who were previously infected with the coronavirus, a third dose of an mRNA vaccine from Pfizer/BioNTech or Moderna may not boost their protection against the Omicron variant of the virus, according to new data.
How Can We Engage Patients and Physicians in the “Next Big Thing?”Annual Reports, Antimicrobials, April 2022, Caregivers, Coronavirus Disease (COVID-19) Pandemic, Digital therapeutics, Doctors, HCPs, Issue Archives, Marketing & Advertising, Med Ad News, Messenger RNA, Patients, Physicians, Sander Flaum Column
Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”
On the heels of the Point of Care Marketing Association’s 2022 Industry Summit and in partnership with leading medical market research company MedSurvey, Havas Media Group (HMG) revealed findings from a new research study examining the matrix of influence surrounding prescribing drugs for patients. The findings identify who beyond MDs exerts influence over prescribing decisions, as well as the concerns, behaviors, trigger moments, and media habits of these influencers.
Some immune system memory persists year after infection; COVID from Omicron also less severe for pregnant womenAntibodies, China, Coronavirus Infections, COVID-19 Studies, COVID-19 Vaccinations, Doctors, Immune System, JAMA, Omicron (B.1.1.529) (South Africa), Omicron BA.2, Pregnancies, R&D, Texas, The Lancet Microbe, Women
A year after infection with the coronavirus – when antibodies in the blood are barely detectable – the immune system continues to “remember” the virus and should respond to some extent upon re-encountering it, a study from China suggests. According to new research, women who were pregnant during the recent Omicron surge had more than eight times the rate of COVID-19 diagnoses, but lower odds of severe illness compared with pregnant women diagnosed earlier in the pandemic.
Patient groups mounted a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars on television and local advertisements that began running during the March 13 morning political shows.
A national survey by Press Ganey – the leader in healthcare consumer and employee experience – revealed heightened consumer expectations and information needs from pharma brands, presenting a unique opportunity for life sciences companies to drive brand strength.
Read Roberts, director of Key Opinion Leaders (KOL) data solutions at PRECISIONscientia, believes 2022 will see social media platforms as the new method for handling pharma medical education and peer-to-peer communications. So pharma must embrace a new type of digital sleuthing to find KOLs and Digital Opinion Leaders (DOLs), but they must do so carefully and think how to mitigate many risks in this highly regulated market, according to Roberts.
Paxlovid Deal Details and Assessment of Pandemic Response BeginsAntiparasitics, Antivirals, Biotechnology, BNT162b2 (Pfizer and BioNTech), Boston University, Business, Children, Contracts, Coronavirus Disease (COVID-19) Pandemic, Covid-19 Data, COVID-19 Doses, COVID-19 Mortality, COVID-19 Vaccines, Cuba, Doctors, Inflammation, Ivermectin, Janssen COVID-19 Vaccine (J&J), Johns Hopkins, Nature, Omicron (B.1.1.529) (South Africa), Omicron BA.2, Paxlovid, Pfizer, R&D, RNA Polymerase, T-Cells, U.S. government, University of Michigan
Aside from vaccines, the advent of several effective COVID-19 antiviral therapies, including Pfizer’s Paxlovid, provides hope for ending the pandemic. Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
More than 100,000 Americans died from diabetes in 2021, marking the second consecutive year for that grim milestone and spurring a call for a federal mobilization similar to the fight against HIV/AIDS.